Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Immunomedics Inc (IMMU)

Immunomedics Inc (IMMU)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,375,961
  • Shares Outstanding, K 193,354
  • Annual Sales, $ 2,160 K
  • Annual Income, $ -273,840 K
  • 60-Month Beta 2.13
  • Price/Sales 1,537.15
  • Price/Cash Flow N/A
  • Price/Book 141.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.45
  • Number of Estimates 4
  • High Estimate -0.39
  • Low Estimate -0.52
  • Prior Year -0.50
  • Growth Rate Est. (year over year) +10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.93 +23.47%
on 10/14/19
17.88 -3.80%
on 11/06/19
+3.03 (+21.38%)
since 10/11/19
3-Month
12.05 +42.74%
on 09/30/19
17.88 -3.80%
on 11/06/19
+2.13 (+14.13%)
since 08/09/19
52-Week
11.55 +48.92%
on 01/18/19
21.53 -20.11%
on 11/12/18
-4.26 (-19.87%)
since 11/09/18

Most Recent Stories

More News
Clovis (CLVS) Q3 Earnings & Sales Beat Estimates, Shares Up

Clovis (CLVS) reports encouraging third-quarter 2019 results. The company tightens guidance for product sales in 2019.

BMY : 58.15 (+0.22%)
IMMU : 17.20 (-1.49%)
CLVS : 5.38 (-8.50%)
ALKS : 19.87 (-1.19%)
Immunomedics (IMMU) Reports Wider-Than-Expected Loss in Q3

Immunomedics' (IMMU) loss lags estimates in Q3. The company fails to generate any revenues at the same time.

RHHBY : 37.5550 (+0.44%)
ANIK : 60.23 (+0.02%)
IMMU : 17.20 (-1.49%)
ACOR : 2.19 (-6.41%)
Immunomedics (IMMU) Reports Wider-Than-Expected Loss in Q3

Immunomedics' (IMMU) loss lags estimates in Q3. The company fails to generate any revenues at the same time.

RHHBY : 37.5550 (+0.44%)
ANIK : 60.23 (+0.02%)
IMMU : 17.20 (-1.49%)
ACOR : 2.19 (-6.41%)
Immunomedics: 3Q Earnings Snapshot

MORRIS PLAINS, N.J. (AP) _ Immunomedics Inc. (IMMU) on Wednesday reported a loss of $94.3 million in its third quarter.

IMMU : 17.20 (-1.49%)
Immunomedics Reports Third Quarter 2019 Results and Provides Corporate Update

TROPHY-U-01 Reached Target Enrollment in Cisplatin-Eligible Cohort of 100 Patients

IMMU : 17.20 (-1.49%)
Immunomedics to Report Third Quarter 2019 Results and Host Conference Call and Webcast on October 30, 2019

Immunomedics, Inc. (NASDAQ: IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it will host a conference call...

IMMU : 17.20 (-1.49%)
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Healthcare Services Group, Heron Therapeutics, Immunomedics, and Karyopharm and Encourages Investors to Contact the Firm

Bragar Eagel & Squire is investigating certain officers and directors of Healthcare Services Group, In. (NASDAQ: HCSG), Heron Therapeutics, Inc. (NASDAQ: HRTX), Immunomedics, Inc. (NASDAQ: IMMU), and Karyopharm...

HCSG : 25.61 (+0.91%)
HRTX : 20.59 (-4.10%)
IMMU : 17.20 (-1.49%)
KPTI : 15.28 (+3.80%)
Patients Turn to Assistance Programs for Aid in the Fight Against Chronic Diseases

With the advancement of the cancer therapy market, new forms of treatment are now being studied and manufactured. Additionally, demand is expected to keep growing for currently effective treatments. Not...

CRIS : 1.46 (-1.35%)
IMMU : 17.20 (-1.49%)
ZIOP : 4.20 (-5.41%)
ONPH : 0.0302 (-2.58%)
Immunomedics (IMMU) Reports Interim Urothelial Cancer Data

Immunomedics (IMMU) presents interim data on sacituzumab govitecan in patients with metastatic urothelial cancer. The company also inks two deals.

RHHBY : 37.5550 (+0.44%)
MRK : 83.28 (-0.37%)
IMMU : 17.20 (-1.49%)
SGEN : 108.30 (-0.04%)
Immunomedics to Present at the 2019 Cantor Global Healthcare Conference

Immunomedics, Inc. (NASDAQ: IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that Dr. Behzad Aghazadeh, Executive...

IMMU : 17.20 (-1.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

See More Share

Trade IMMU with:

Business Summary

Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized...

See More

Key Turning Points

2nd Resistance Point 17.62
1st Resistance Point 17.41
Last Price 17.20
1st Support Level 17.03
2nd Support Level 16.86

See More

52-Week High 21.53
Fibonacci 61.8% 17.72
Last Price 17.20
Fibonacci 50% 16.54
Fibonacci 38.2% 15.36
52-Week Low 11.55

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar